U.S. patent application number 10/293551 was filed with the patent office on 2003-06-26 for erythropoietin conjugates.
Invention is credited to Bailon, Pascal Sebastian.
Application Number | 20030120045 10/293551 |
Document ID | / |
Family ID | 27495518 |
Filed Date | 2003-06-26 |
United States Patent
Application |
20030120045 |
Kind Code |
A1 |
Bailon, Pascal Sebastian |
June 26, 2003 |
Erythropoietin conjugates
Abstract
Conjugates of erythropoietin with poly(ethylene glycol) comprise
an erythropoietin glycoprotein having at least one free amino group
and having the in vivo biological activity of causing bone marrow
cells to increase production of reticulocytes and red blood cells
and selected from the group consisting of human erythropoietin and
analogs thereof which have sequence of human erythropoietin
modified by the addition of from 1 to 6 glycosylation sites or a
rearrangement of at least one glycosylation site; said glycoprotein
being covalently linked to "n" poly(ethylene glycol) groups of the
formula --CO--(CH.sub.2).sub.x(OCH.su- b.2CH.sub.2).sub.m--OR with
the carbonyl of each poly(ethylene glycol) group forming an amide
bond with one of said amino groups; wherein R is lower alkyl; x is
2 or 3; m is about 450 to about 900; n is from 1 to 3; and n and m
are chosen so that the molecular weight of the conjugate minus the
erythropoietin glycoprotein is from 20 kilodaltons to 100
kilodaltons.
Inventors: |
Bailon, Pascal Sebastian;
(Florham Park, NJ) |
Correspondence
Address: |
GIBBONS, DEL DEO, DOLAN, GRIFFINGER & VECCHIONE
1 RIVERFRONT PLAZA
NEWARK
NJ
07102-5497
US
|
Family ID: |
27495518 |
Appl. No.: |
10/293551 |
Filed: |
November 14, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10293551 |
Nov 14, 2002 |
|
|
|
09604938 |
Jun 27, 2000 |
|
|
|
60142254 |
Jul 2, 1999 |
|
|
|
60150225 |
Aug 23, 1999 |
|
|
|
60151548 |
Aug 31, 1999 |
|
|
|
60166151 |
Nov 17, 1999 |
|
|
|
Current U.S.
Class: |
530/397 |
Current CPC
Class: |
A61P 13/12 20180101;
A61K 47/60 20170801; A61P 7/06 20180101; A61P 37/00 20180101; A61P
31/00 20180101; C07K 17/08 20130101; A61P 7/00 20180101; A61P 25/18
20180101; A61P 35/00 20180101; C07K 14/505 20130101; A61P 31/18
20180101; A61K 47/62 20170801 |
Class at
Publication: |
530/397 |
International
Class: |
C07K 014/575 |
Claims
What is claimed is:
1. A conjugate comprising an erythropoietin glycoprotein having a
free amino group and having the in vivo biological activity of
causing bone marrow cells to increase production of reticulocytes
and red blood cells and selected from the group consisting of human
erythropoietin and analogs thereof which have sequence of human
erythropoietin modified by the addition of from 1 to 6
glycosylation sites or a rearrangement of at least one
glycosylation site; said glycoprotein being covalently linked to
"n" poly(ethylene glycol) groups of the formula
--CO--(CH.sub.2).sub.x--(OCH.sub.2CH.sub.2).sub.m--OR by the --CO
of said poly(ethylene glycol) group forming an amide bond with said
amino groups; wherein R is lower alkyl; x is 2 or 3; m is from
about 450 to about 900; and m is chosen so that the molecular
weight of the conjugates minus the erythropoietin glycoprotein is
from 20 kilodaltons to 100 kilodaltons.
2. The conjugate of claim 1, of the
formula:P--[NHCO--(CH.sub.2).sub.x--(O-
CH.sub.2CH.sub.2).sub.m--OR].sub.n (I)wherein m, n and R are as
above, and P is the residue of the glycoprotein without the n amino
group(s) which form amide linkage(s) with the poly(ethylene glycol)
group(s).
3. The conjugate of claim 2 wherein x is 3.
4. The conjugate of claim 3 wherein n is 1.
5. The conjugate of claim 4 wherein said molecular weight is from
about 20 kDa to about 40 kDa.
6. The conjugate of claim 5 wherein said molecular weight is about
30 kDa.
7. The conjugate of claim 2, wherein the glycoprotein has the
sequence of human erythropoietin modified by the addition of from 1
to 6 glycosylation sites.
8. The conjugate of claim 2, wherein the glycoprotein has the
sequence of human erythropoietin modified by the rearrangement of
at least one glycosylation site.
9. The conjugate of claim 8 wherein n is 1.
10. The conjugate of claim 2 wherein the glycoprotein is human
erythropoietin.
11. The conjugate of claim 8, wherein the human erythropoietin
glycoprotein is expressed by endogenous gene activation.
12. The conjugate of claim 10, wherein the glycoprotein has the
sequence SEQ ID NO:1.
13. The conjugate of claim 12, wherein R is methyl.
14. The congjugate of claim 7 wherein the glycopprotein has the
sequence of human erythropoietin modified by a modification
selected from the group consisting of: Asn.sup.30Thr.sup.32;
Asn.sup.51Thr.sup.53, Asn.sup.57Thr.sup.59; Asn.sup.69;
Asn.sup.69Thr.sup.71; Ser.sup.68Asn.sup.69Thr.sup.71;
Val.sup.87Asn.sup.88Thr.sup.90; Ser.sup.87Asn.sup.88Thr.sup.90;
Ser.sup.87Asn.sup.88Gly.sup.89Thr.sup.90;
Ser.sup.87Asn.sup.88Thr.sup.90Thr.sup.92;
Ser.sup.87Asn.sup.88Thr.sup.90 Ala.sup.162;
Asn.sup.69Thr.sup.71Ser.sup.87 Asn.sup.88Thr.sup.90;
Asn.sup.30Thr.sup.32Val.sup.87 Asn.sup.88Thr.sup.90;
Asn.sup.89Ile.sup.90Thr.sup.91; Ser.sup.87
Asn.sup.89Ile.sup.90Thr.sup.91- ; Asn.sup.136Thr.sup.138;
Asn.sup.138Thr.sup.140; Thr.sup.125; and
Pro.sup.124Thr.sup.125.
15. The conjugate of claim 7, wherein the rearrangement comprises
deletion of any of the N-linked glycosylation sites in human
erythropoietin and addition of an N-linked glycosylation site at
position 88 of the sequence of human erythropoietin.
16. The conjugate of claim 2, wherein the glycoprotein has the
sequence of human erythropoietin modified by a modification
selected from the group consisting of: Gln.sup.24 Ser.sup.87
Asn.sup.88 Thr.sup.90; Gln.sup.38 Ser.sup.87 Asn.sup.88 Thr.sup.90;
and Gln.sup.83 Ser.sup.87 Asn.sup.88 Thr.sup.90.
17. The conjugate of claim 16, wherein R is methyl.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The priority of U.S. Provisional Application No. 60/142,254,
filed Jul. 2, 1999; No. 60/150,225, filed Aug. 23, 1999; No.
60/151,548, filed Aug. 31, 1999; No. 60/166,151, filed Nov. 17,
1999 and U.S. application Ser. No. 09/604,938, filed Jun. 27, 2000
is claimed.
BACKGROUND OF THE INVENTION
[0002] Erythropoiesis is the production of red blood cells, which
occurs to offset cell destruction. Erythropoiesis is a controlled
physiological mechanism that enables sufficient red blood cells to
be available for proper tissue oxygenation. Naturally occurring
human erythropoietin (hEPO) is produced in the kidney and is the
humoral plasma factor which stimulates red blood cell production
(Carnot, P and Deflandre, C (1906) C.R. Acad. Sci. 143: 432;
Erslev, A J (1953 Blood 8: 349; Reissmann, K R (1950) Blood 5: 372;
Jacobson, L O, Goldwasser, E, Freid, W and Plzak, L F (1957) Nature
179: 6331-4). Naturally occurring EPO stimulates the division and
differentiation of committed erythroid progenitors in the bone
marrow and exerts its biological activity by binding to receptors
on erythroid precursors (Krantz, B S (1991) Blood 77: 419).
[0003] Erythropoietin has been manufactured biosynthetically using
recombinant DNA technology (Egrie, J C, Strickland, T W, Lane, J et
al. (1986) Immunobiol. 72: 213-224) and is the product of a cloned
human EPO gene inserted into and expressed in the ovarian tissue
cells of the chinese hamster (CHO cells). The primary structure of
the predominant, fully processed form of hEPO is illustrated in SEQ
ID NO:1. There are two disulfide bridges between
Cys.sup.7-Cys.sup.161 and Cys.sup.29-Cys.sup.33. The molecular
weight of the polypeptide chain of EPO without the sugar moieties
is 18,236 Da. In the intact EPO molecule, approximately 40% of the
molecular weight are accounted for by the carbohydrate groups that
glycosylate the protein at glycosylation sites on the protein
(Sasaki, H, Bothner, B, Dell, A and Fukuda, M (1987) J. Biol. Chem.
262: 12059).
[0004] Because human erythropoietin is essential in red blood cell
formation, the hormone is useful in the treatment of blood
disorders characterized by low or defective red blood cell
production. Clinically, EPO is used in the treatment of anemia in
chronic renal failure patients (CRF) (Eschbach, J W, Egri, J C,
Downing, M R et al. (1987) NEJM 316: 73-78; Eschbach, J W,
Abdulhadi, M H, Browne, J K et al. (1989) Ann. Intern. Med. 111:
992; Egrie, J C, Eschbach, J W, McGuire, T, Adamson, J W (1988)
Kidney Intl. 33: 262; Lim, V S, Degowin, R L, Zavala, D et al.
(1989) Ann. Intern. Med. 110: 108-114) and in AIDS and cancer
patients undergoing chemotherapy (Danna, R P, Rudnick, S A, Abels,
R I In: M B, Garnick, ed. Erythropoietin in Clinical
Applications--An International Perspective. New York, N.Y.: Marcel
Dekker; 1990: p. 301-324). However, the bioavailability of
commercially avilable protein therapeutics such as EPO is limited
by their short plasma half-life and susceptibility to protease
degradation. These shortcomings prevent them from attaining maximum
clinical potency.
SUMMARY OF THE INVENTION
[0005] This invention provides an erythropoietin conjugate, said
conjugate comprising an erythropoietin glycoprotein having at least
one free amino group and having the in vivo biological activity of
causing bone marrow cells to increase production of reticulocytes
and red blood cells and selected from the group consisting of human
erythropoietin and analogs thereof which have sequence of human
erythropoietin modified by the addition of from 1 to 6
glycosylation sites or a rearrangement of at least one
glycosylation site; said glycoprotein being covalently linked to
"n" poly(ethylene glycol) groups of the formula
--CO--(CH.sub.2).sub.x--(OCH.sub.2CH.sub.2).sub.m--OR with the --CO
(i.e. carbonyl) of each poly(ethylene glycol) group forming an
amide bond with one of said amino groups; wherein R is lower alkyl;
x is 2 or 3; m is from about 450 to about 900; n is from 1 to 3;
and n and m are chosen so that the molecular weight of the
conjugate minus the erythropoietin glycoprotein is from 20
kilodaltons to 100 kilodaltons. This invention further provides
compositions containing conjugates described herein in which the
percentage of conjugates in the composition in which n is 1 is at
least ninety percent.
[0006] Compared to unmodified EPO (i.e., EPO without a PEG
attached) and conventional PEG-EPO conjugates, the present
conjugates have an increased circulating half-life and plasma
residence time, decreased clearance, and increased clinical
activity in vivo. The conjugates of this invention have the same
uses as EPO. In particular, the conjugates of this invention are
useful to treat patients by stimulating the division and
differentiation of committed erythroid progenitors in the bone
marrow in the same way EPO is used to treat patients.
BRIEF DESCRIPTION OF THE FIGURES
[0007] FIG. 1: Influence of pH on thermal stability. The transition
temperature is plotted against the pH.
[0008] FIG. 2: Influence of ionic strength on thermal stability.
The transition temperature is plotted against the phosphate
concentration.
[0009] FIG. 3: Dependence of thermal stability on buffer
substance.
[0010] FIG. 4 shows that sulfate is also a suitable buffer/additive
at low pH (e.g. pH 6.2), whereas phosphate is less suitable at pH
6.2 compared to pH 7.5. This shows that sulfate keeps the thermal
stability high, even at low pH.
[0011] FIG. 5: Dependency of peg-EPO aggregation on pH. Peg-EPO
samples after heat stress (as described above) were analyzed by
SDS-PAGE. Proteins were stained with silver. Lane 1: molecular
weight standard. Lane 2: pH 5. Lane 3: pH 5, reduced. Lane 4: pH 6.
Lane 5: pH 6, reduced. Lane 6: pH 6.5. Lane 7: pH 6.5, reduced.
Lane 8: pH 7. Lane 9: pH 7, reduced. Lane 10: peg-EPO,
unstressed.
[0012] FIG. 6 shows that the use of 1 mg/ml acetylcysteine as an
antioxidant prevents the formation of aggregates under heat
stress.
DETAILED DESCRIPTION OF THE INVENTION
[0013] This invention provides conjugates, said conjugates
comprising an erythropoietin glycoprotein having at least one free
amino group and having the in vivo biological activity of causing
bone marrow cells to increase production of reticulocytes and red
blood cells and selected from the group consisting of human
erythropoietin and analogs thereof which have sequence of human
erythropoietin modified by the addition of from 1 to 6
glycosylation sites or a rearrangement of at least one
glycosylation site; said glycoprotein being covalently linked to
"n" poly(ethylene glycol) groups of the formula
--CO--(CH.sub.2).sub.x--(OCH.- sub.2CH.sub.2).sub.m--OR with the
--CO (i.e. carbonyl) of each poly(ethylene glycol) group forming an
amide bond with one of said amino groups; wherein R is lower alkyl;
x is 2 or 3; m is from about 450 to about 900; n is from 1 to 3;
and n and m are chosen so that the molecular weight of the
conjugate minus the erythropoietin glycoprotein is from 20
kilodaltons to 100 kilodaltons.
[0014] It has been found that the conjugates of this invention can
be used in the same manner as unmodified EPO. However, the
conjugates of this invention have an increased circulating
half-life and plasma residence time, decreased clearance, and
increased clinical activity in vivo. Because of these improved
properties, the conjugates of this invention can be administered
once weekly instead of the three times weekly for unmodified EPO.
Decreased frequency of administration is expected to result in
improved patient compliance leading to improved treatment outcomes,
as well as improved patient quality of life. Compared to
conventional conjugates of EPO linked to poly(ethylene glycol) it
has been found that conjugates having the molecular weight and
linker structure of the conjugates of this invention have an
improved potency, stability, AUC, circulating half-life, and cost
of goods profile.
[0015] The conjugates in accordance of this invention can be
administered in a therapeutically effective amount to patients in
the same way EPO is administered. The therapeutically effective
amount is that amount of conjugate necessary for the in vivo
biological activity of causing bone marrow cells to increase
production of reticulocytes and red blood cells. The exact amount
of conjugate is a matter of preference subject to such factors as
the exact type of condition being treated, the condition of the
patient being treated, as well as the other ingredients in the
composition. The pharmaceutical compositions containing the
conjugate may be formulated at a strength effective for
administration by various means to a human patient experiencing
blood disorders characterized by low or defective red blood cell
production. Average therapeutically effective amounts of the
conjugate may vary and in particular should be based upon the
recommendations and prescription of a qualified physician.
[0016] The erythropoietin glycoprotein products prepared in
accordance with this invention may be prepared in pharmaceutical
compositions suitable for injection with a pharmaceutically
acceptable carrier or vehicle by methods known in the art. Among
the preferred pharmaceutically acceptable carriers for formulating
the products of the invention are human serum album, human plasma
proteins, etc.
[0017] The term "erythropoietin" or "EPO" refers to a glycoprotein,
having the amino acid sequence set out in (SEQ ID NO: 1) or (SEQ ID
NO: 2) or an amino acid sequence substantially homologous thereto,
whose biological properties relate to the stimulation of red blood
cell production and the stimulation of the division and
differentiation of committed erythroid progenitors in the bone
marrow. As used herein, these terms include such proteins modified
deliberately, as for example, by site directed mutagenesis or
accidentally through mutations. These terms also include analogs
having from 1 to 6 additional sites for glycosylation, analogs
having at least one additional amino acid at the carboxy terminal
end of the glycoprotein, wherein the additional amino acid includes
at least one glycosylation site, and analogs having an amino acid
sequence which includes a rearrangement of at least one site for
glycosylation. These terms include both natural and recombinantly
produced human erythropoietin.
[0018] The erythropoietin conjugates of this invention can be
represented by Formula 1:
P--[NHCO--(CH.sub.2).sub.x--(OCH.sub.2CH.sub.2).sub.m--OR].sub.n
(I)
[0019] wherein x, m, n and R are as above.
[0020] In Formula I, P is the residue of an erythropoietin
glycoprotein described herein, (i.e. without the amino group or
amino groups which form an amide linkage with the carbonyl shown in
Formula I), having the in vivo biological activity of causing bone
marrow cells to increase production of reticulocytes and red blood
cells. P may be selected from the group consisting of residues of
human erythropoietin and analogs thereof having from 1 to 6
additional sites for glycosylation. As set out in detail below, the
preparation and purification of EPO are well known in the art. By
EPO is meant the natural or recombinant protein, preferably human,
as obtained from any conventional source such as tissues, protein
synthesis, cell culture with natural or recombinant cells. Any
protein having the activity of EPO, such as muteins or otherwise
modified proteins, is encompassed. Recombinant EPO may be prepared
via expression in CHO-, BHK- or HeLa cell lines, by recombinant DNA
technology or by endogenous gene activation. Expression of
proteins, including EPO, by endogenous gene activation is well
known in the art and is disclosed, for example in U.S. Pat. Nos.
5,733,761, 5,641,670, and 5,733,746, and international patent
publication Nos. WO 93/09222, WO 94/12650, WO 95/31560, WO
90/11354, WO 91/06667 and WO 91/09955, the contents of each of
which are incorporated herein by reference. The preferred EPO
species for the preparation of erythropoietin glycoprotein products
are human EPO species. More preferably, the EPO species is the
human EPO having the amino acid sequence set out in SEQ ID NO:1 or
SEQ ID NO:2, more preferably the amino acid sequence SEQ ID
NO:1.
[0021] In an embodiment, P may be the residue of a glycoprotein
analog having from 1 to 6 additional sites for glycosylation.
Glycosylation of a protein, with one or more oligosaccharide
groups, occurs at specific locations along a polypeptide backbone
and greatly affects the physical properties of the protein such as
protein stability, secretion, subcellular localization, and
biological activity. Glycosylation is usually of two types.
O-linked oligosaccharides are attached to serine or threonine
residues and N-linked oligosaccharides are attached to asparagine
residues. One type of oligosaccharide found on both N-linked and
O-linked oligosaccharides is N-acetylneuraminic acid (sialic acid),
which is a family of amino sugars containing 9 or more carbon
atoms. Sialic acid is usually the terminal residue on both N-linked
and O-linked oligosaccharides and, because it bears a negative
charge, confers acidic properties to the glycoprotein. Human
erythropoietin, having 165 amino acids, contains three N-linked and
one O-linked oligosaccharide chains which comprise about 40% of the
total molecular weight of the glycoprotein. N-linked glycosylation
occurs at asparagine residues located at positions 24, 38, and 83
and O-linked glycosylation occurs at a serine residue located at
position 126. The oligosaccharide chains are modified with terminal
sialic acid residues. Enzymatic removal of all sialic acid residues
from the glycosylated erythropoietin results in loss of in vivo
activity but not in vitro activity because sialylation of
erythropoietin prevents its binding, and subsequent clearance, by
hepatic binding protein.
[0022] The glycoproteins of the present invention include analogs
of human erythropoietin with one or more changes in the amino acid
sequence of human erythropoietin which result in an increase in the
number of sites for sialic acid attachment. These glycoprotein
analogs may be generated by site-directed mutagenesis having
additions, deletions, or substitutions of amino acid residues that
increase or alter sites that are available for glycosylation.
Glycoprotein analogs having levels of sialic acid greater than
those found in human erythropoietin are generated by adding
glycosylation sites which do not perturb the secondary or tertiary
conformation required for biological activity. The glycoproteins of
the present invention also include analogs having increased levels
of carbohydrate attachment at a glycoslyation site which usually
involve the substitution of one or more amino acids in close
proximity to an N-linked or O-linked site. The glycoproteins of the
present invention also include analogs having one or more amino
acids extending from the carboxy terminal end of erythropoietin and
providing at least one additional carbohydrate site. The
glycoproteins of the present invention also include analogs having
an amino acid sequence which includes a rearrangement of at least
one site for glycosylation. Such a rearrangement of glycosylation
site involves the deletion of one or more glycosylation sites in
human erythropoietin and the addition of one or more non-naturally
occurring glycosylation sites. Increasing the number of
carbohydrate chains on erythropoietin, and therefore the number of
sialic acids per erythropoietin molecules may confer advantageous
properties such as increased solubility, greater resistance to
proteolysis, reduced immunogenecity, increased serum half-life, and
increased biological activity. Erythropoietin analogs with
additional glycosylation sites are disclosed in more detail in
European Patent Application 640 619, to Elliot published Mar. 1,
1995.
[0023] In a preferred embodiment, the glycoproteins of the present
invention comprise an amino acid sequence which includes at least
one additional site for glycosylation such as, but not limited to,
erythropoietins comprising the sequence of human erythropoietin
modified by a modification selected from the following:
[0024] Asn.sup.30Thr.sup.32;
[0025] Asn.sup.51Thr.sup.53,
[0026] Asn.sup.57Thr.sup.59;
[0027] Asn.sup.69;
[0028] Asn.sup.69Thr.sup.71;
[0029] Ser.sup.68Asn.sup.69Thr.sup.71;
[0030] Val.sup.87Asn.sup.88Thr.sup.90;
[0031] Ser.sup.87Asn.sup.88Thr.sup.90;
[0032] Ser.sup.87Asn.sup.88Gly.sup.89Thr.sup.90;
[0033] Ser.sup.87Asn.sup.88Thr.sup.90Thr.sup.92;
[0034] Ser.sup.87Asn.sup.88Thr.sup.90Ala.sup.162;
[0035] Asn.sup.69Thr.sup.71Ser.sup.87Asn.sup.88Thr.sup.90;
[0036] Asn.sup.30Thr.sup.32Val.sup.87Asn.sup.88Thr.sup.90;
[0037] Asn.sup.89Ile.sup.90Thr.sup.91;
[0038] Ser.sup.87Asn.sup.89Ile.sup.90Thr.sup.91;
[0039] Asn.sup.136Thr.sup.138;
[0040] Asn.sup.138Thr.sup.140;
[0041] Thr.sup.125; and
[0042] Pro.sup.124Thr.sup.125.
[0043] The notation used herein for modification of amino acid
sequence means that the position(s) of the corresponding unmodified
protein (e.g. hEPO of SEQ ID NO:1 or SEQ ID NO:2) indicated by the
superscripted number(s) is changed to the amino acid(s) that
immediately precede the respective superscripted number(s).
[0044] The glycoprotein may also be an analog having at least one
additional amino acid at the carboxy terminal end of the
glycoprotein, wherein the additional amino acid includes at least
one glycosylation site. The additional amino acid may comprise a
peptide fragment derived from the carboxy terminal end of human
chorionic gonadotropin. Preferably, the glycoprotein is an analog
selected from the group consisting of (a) human erythropoietin
having the amino acid sequence, Ser Ser Ser Ser Lys Ala Pro Pro Pro
Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro IIe Leu
Pro Gln (SEQ ID NO:3), extending from the carboxy terminus; (b) the
analog in (a) further comprising Ser.sup.87 Asn.sup.88 Thr.sup.90
EPO; and (c) the analog in (a) further comprising Asn.sup.30
Thr.sup.32 Val.sup.87 Asn.sup.88 Thr.sup.90 EPO.
[0045] The glycoprotein may also be an analog having an amino acid
sequence which includes a rearrangement of at least one site for
glycosylation. The rearrangement may comprise a deletion of any of
the N-linked carbohydrate sites in human erythropoietin and an
addition of an N-linked carbohydrate site at position 88 of the
amino acid sequence of human erythropoietin. Preferably, the
glycoprotein is an analog selected from the group consisting of
Gln.sup.24 Ser.sup.87 Asn.sup.88 Thr.sup.90 EPO; Gln.sup.38
Ser.sup.87 Asn.sup.88 Thr.sup.90 EPO; and Gln.sup.83 Ser.sup.87
Asn.sup.88 Thr.sup.90 EPO.
[0046] As used herein, "lower alkyl" means a linear or branched
alkyl group having from one to six carbon atoms. Examples of lower
alkyl groups include methyl, ethyl and isopropyl. In accordance
with this invention, R is any lower alkyl. Conjugates in which R is
methyl are preferred.
[0047] The symbol "m" represents the number of ethylene oxide
residues (OCH.sub.2CH.sub.2) in the poly(ethylene oxide) group. A
single PEG subunit of ethylene oxide has a molecular weight of
about 44 daltons. Thus, the molecular weight of the conjugate
(excluding the molecular weight of the EPO) depends on the number
"m". In the conjugates of this invention "m" is from about 450 to
about 900 (corresponding to a molecular weight of about 20 kDa to
about 40 kDa), preferably from about 650 to about 750
(corresponding to a molecular weight of about 30 kDa). The number m
is selected such that the resulting conjugate of this invention has
a physiological activity comparable to unmodified EPO, which
activity may represent the same as, more than, or a fraction of the
corresponding activity of unmodified EPO. A molecular weight of
"about" a certain number means that it is within a reasonable range
of that number as determined by conventional analytical techniques.
The number "m" is selected so that the molecular weight of each
poly(ethylene glycol) group covalently linked to the erythropoietin
glycoprotein is from about 20 kDa to about 40 kDa, and is
preferably about 30 kDa.
[0048] In the conjugates of this invention, the number "n is the
number of polyethylene glycol groups covalently bound to free amino
groups (including .epsilon. amino groups of a lysine amino acid
and/or the amino-terminal amino group) of an erythropoietin protein
via amide linkage(s). A conjugate of this invention may have one,
two, or three PEG groups per molecule of EPO. "n" is an integer
ranging from 1 to 3, preferably "n" is 1 or 2, and more preferably
"n" is 1.
[0049] The compound of Formula I can be prepared from the known
polymeric material: 1
[0050] in which R and m are as described above, by condensing the
compound of Formula II with the erythropoietin glycoprotein.
Compounds of Formula II in which x is 3 are alpha-lower alkoxy,
butyric acid succinimidyl esters of poly(ethylene glycol) (lower
alkoxy-PEG-SBA). Compounds of Formula II in which x is 2 are
alpha-lower alkoxy, propionic acid succinimidyl esters of
poly(ethylene glycol) (lower alkoxy-PEG-SPA). Any conventional
method of reacting an activated ester with an amine to form an
amide can be utilized. In the reaction described above, the
exemplified succinimidyl ester is a leaving group causing the amide
formation. The use of succinimidyl esters such as the compounds of
formula II to produce conjugates with proteins are disclosed in
U.S. Pat. No. 5,672,662, issued Sep. 30, 1997 (Harris, et al.).
[0051] Human EPO contains nine free amino groups, the
amino-terminal amino group plus the .epsilon.-amino groups of 8
lysine residues. When the pegylation reagent was combined with a
SBA compound of Formula II, it has been found that at pH 7.5, a
protein:PEG ratio of 1:3, and a reaction temperature of from
20-25.degree. C., a mixture of mono-, di-, and trace amounts of the
tri-pegylated species were produced. When the pegylation reagent
was a SPA compound of Formula II, at similar conditions except that
the protein:PEG ratio was 1:2, primarily the mono-pegylated species
is produced. The pegylated EPO can be administered as a mixture, or
as the cation exchange chromatography separated different pegylated
species. By manipulating the reaction conditions (e.g., ratio of
reagents, pH, temperature, protein concentration, time of reaction
etc.), the relative amounts of the different pegylated species can
be varied.
[0052] Human erythropoietin (EPO) is a human glycoprotein which
stimulates the formation of erythrocytes. Its preparation and
therapeutic application are described in detail for example in U.S.
Pat. Nos. 5,547,933 and 5,621,080, EP-B 0 148 605, Huang, S. L.,
Proc. Natl. Acad. Sci. USA (1984) 2708-2712, EP-B 0 205 564, EP-B 0
209 539 and EP-B 0 411 678 as well as Lai, P. H. et al., J. Biol.
Chem. 261 (1986) 3116-3121, an Sasaki, H. et al., J. Biol. Chem.
262 (1987) 12059-12076. Erythropoietin for therapeutic uses may be
produced by recombinant means (EP-B 0 148 605, EP-B 0 209 539 and
Egrie, J. C., Strickland, T. W., Lane, J. et al. (1986) Immunobiol.
72: 213-224).
[0053] Methods for the expression and preparation of erythropoietin
in serum free medium are described for example in WO 96/35718, to
Burg published Nov. 14, 1996, and in European Patent Publication
No. 513 738, to Koch published Jun. 12, 1992. In addition to the
publications mentioned above, it is known that a serum-free
fermentation of recombinant CHO cells which contain an EPO gene can
be carried out. Such methods are described for example in EP-A 0
513 738, EP-A 0 267 678 and in a general form by Kawamoto, T. et
al., Analytical Biochem. 130 (1983) 445-453, EP-A 0 248 656, Kowar,
J. and Franek, F., Methods in Enzymology 421 (1986) 277-292,
Bavister, B., Expcology 271 (1981) 45-51, EP-A 0 481 791, EP-A 0
307 247, EP-A 0 343 635, WO 88/00967.
[0054] In EP-A 0 267 678 an ion exchange chromatography on
S-Sepharose, a preparative reverse phase HPLC on a C.sub.8 column
and a gel filtration chromatography are described for the
purification of EPO produced in serum-free culture after dialysis.
In this connection the gel filtration chromatography step can be
replaced by ion exchange chromatography on S-Sepharose fast flow.
It is also proposed that a dye chromatography on a Blue Trisacryl
column be carried out before the ion exchange chromatography.
[0055] A process for the purification of recombinant EPO is
described by Nobuo, I. et al., J. Biochem. 107 (1990) 352-359. In
this process EPO is treated however with a solution of Tween.RTM.
20, phenylmethylsulfonyl fluoride, ethylmaleimide, pepstatin A,
copper sulfate and oxamic acid prior to the purification steps.
Publications, including WO 96/35718, to Burg published Nov. 14,
1996, discloses a process for preparing erythropoietin in a serum
free fermentation process (EPOsf).
[0056] The specific activity of EPO or EPO conjugates in accordance
with this invention can be determined by various assays known in
the art. The biological activity of the purified EPO proteins of
this invention are such that administration of the EPO protein by
injection to human patients results in bone marrow cells increasing
production of reticulocytes and red blood cells compared to
non-injected or control groups of subjects. The biological activity
of the EPO proteins, or fragments thereof, obtained and purified in
accordance with this invention can be tested by methods according
to Annable, et al., Bull. Wld. Hlth. Org. (1972) 47: 99-112 and
Pharm. Europa Spec. Issue Erythropoietin BRP Bio 1997(2). Another
biological assay for determining the activity of EPO protein, the
normocythaemic mouse assay, is described in Example 4. This
invention provides a composition comprised of conjugates as
described above. A composition containing at least ninety percent
mono-PEG conjugates, i.e. in which n is 1, can be prepared as shown
in Example 5. Usually mono-PEG conjugates of erythropoietin
glycoproteins are desirable because they tend to have higher
activity than di-PEG conjugates. The percentage of mono-PEG
conjugates as well as the ratio of mono- and di-PEG species can be
controlled by pooling broader fractions around the elution peak to
decrease the percentage of mono-PEG or narrower fractions to
increase the percentage of mono-PEG in the composition. About
ninety percent mono-PEG conjugates is a good balance of yield and
activity. Sometimes compositions in which, for example, at least
ninety-two percent or at least ninety-six percent of the conjugates
are mono-PEG species (n equals 1) may be desired. In an embodiment
of this invention the percentage of conjugates where n is 1 is from
ninety percent to ninety-six percent.
[0057] The invention will be better understood by reference to the
following examples which illustrate but do not limit the invention
described herein.
EXAMPLE 1
[0058] Fermentation and Purification of Human EPO
[0059] a) Inoculum Preparation and Fermentation
[0060] One vial of the Working Cell Bank, originating from an
EPO-producing CHO cell line (ATCC CRL8695, disclosed in EP 411 678
(Genetics Institute) can be used) is taken from the gas phase of
the liquid nitrogen storage tank. The cells are transferred into
glass spinner flasks and cultivated in a hydrogen
carbonate-buffered medium in a humidified CO.sub.2 incubator.
Typical serum free media used for the inocolum preparation and
fermentation are disclosed in European Patent Application 513 738,
to Koch published Jun. 12, 1992, or WO 96/35718, to Burg published
Nov. 14, 1996, for example contain as medium DMEM/F12 (e.g. JRH
Biosciences/Hazleton Biologics, Denver, US, order No. 57-736) and
additionally sodium hydrogencarbonate, L+glutamine, D+glucose,
recombinant insulin, sodium selenite, diaminobutane,
hydrocortisone, iron(II) sulfate, asparagine, aspartic acid, serine
and a stabilizer for mammalian cells such as e.g. polyvinyl
alcohol, methyl cellulose, polydextran, polyethylene glycol,
Pluronic F68, plasma expander polygelin (HEMACCEL.RTM.) or
polyvinyl pyrrolidone (WO 96/35718).
[0061] The cultures are microscopically checked for the absence of
contaminating microorganisms, and the cell densities are
determined. These tests are performed at each splitting step.
[0062] After the initial growth period, the cell culture is diluted
with fresh medium to the starting cell density and undergoes
another growth cycle. This procedure is repeated until a culture
volume of approximately 2 l per glass spinner flask has been
obtained. After approx. 12 doublings 1 to 5 liter of this culture
is available which then is used as inoculum for the 10 l inoculum
fermenter.
[0063] After 3-5 days, the culture in the 10 l fermenter can be
used as inoculum for the 100 l inoculum fermenter.
[0064] After additional 3-5 days of cultivation, the culture in the
100 l fermenter can be used as inoculum for the 1000 l production
fermenter.
[0065] b) Harvesting and Cell Separation
[0066] A batch refeed process is used, i.e. when the desired cell
density is reached, approx. 80% of the culture is harvested. The
remaining culture is replenished with fresh culture medium and
cultivated until the next harvest. One production run consists of a
maximum of 10 subsequent harvests: 9 partial harvests and 1 overall
harvest at the end of fermentation. Harvesting takes place every
3-4 days.
[0067] The determined harvest volume is transferred into a cooled
vessel. The cells are removed by centrifugation or filtration and
discarded. The EPO containing supernatant of the centrifugation
step is in-line filtered and collected in a second cooled vessel.
Each harvest is processed separately during purification.
[0068] A typical process for the purification of EPO-protein is
disclosed in WO 96/35718, to Burg published Nov. 14, 1996. The
purification process is explained in the following.
[0069] a) Blue Sepharose Chromatography
[0070] Blue Sepharose (Pharmacia) consists of Sepharose beads to
the surface of which the Cibacron blue dye is covalently bound.
Since EPO binds more strongly to Blue Sepharose than most
non-proteinaceous contaminants, some proteinaceous impurities and
PVA, EPO can be enriched in this step. The elution of the Blue
Sepharose column is performed by increasing the salt concentration
as well as the pH.
[0071] The column is filled with 80-100 l of Blue Sepharose,
regenerated with NaOH and equilibrated with equilibration buffer
(sodium/calcium chloride and sodium acetate). The acidified and
filtered fermenter supernatant is loaded. After completion of the
loading, the column is washed first with a buffer similar to the
equilibration buffer containing a higher sodium chloride
concentration and consecutively with a Tris-base buffer. The
product is eluted with a Tris-base buffer and collected in a single
fraction in accordance with the master elution profile.
[0072] b) Butyl Toyopearl Chromatography
[0073] The Butyl Toyopearl 650 C (Toso Haas) is a polystyrene based
matrix to which aliphatic butyl-residues are covalently coupled.
Since EPO binds more strongly to this gel than most of the
impurities and PVA, it has to be eluted with a buffer containing
isopropanol.
[0074] The column is packed with 30-40 l of Butyl Toyopearl 650 C,
regenerated with NaOH, washed with a Tris-base buffer and
equilibrated with a Tris-base buffer containing isopropanol.
[0075] The Blue Sepharose eluate is adjusted to the concentration
of isopropanol in the column equilibration buffer and loaded onto
the column. Then the column is washed with equilibration buffer
with increased isopropanol concentration. The product is eluted
with elution buffer (Tris-base buffer with high isopropanol
content) and collected in a single fraction in accordance with the
master elution profile.
[0076] c) Hydroxyapatite Ultrogel Chromatography
[0077] The Hydroxyapatite Ultrogel (Biosepra) consists of
hydroxyapatite which is incorporated in an agarose matrix to
improve the mechanical properties. EPO has a low affinity to
hydroxyapatite and can therefore be eluted at lower phosphate
concentrations than protein impurities.
[0078] The column is filled with 30-40 l of Hydroxyapatite Ultrogel
and regenerated with a potassium phosphate/calcium chloride buffer
and NaOH followed by a Tris-base buffer. Then it is equilibrated
with a Tris-base buffer containing a low amount of isopropanol and
sodium chloride.
[0079] The EPO containing eluate of the Butyl Toyopearl
chromatography is loaded onto the column. Subsequently the column
is washed with equilibration buffer and a Tris-base buffer without
isopropanol and sodium chloride. The product is eluted with a
Tris-base buffer containing a low concentration of potassium
phosphate and collected in a single fraction in accordance with the
master elution profile.
[0080] d) Reversed Phase HPLC on Vydac C4
[0081] The RP-HPLC material Vydac C4 (Vydac)consists of silica gel
particles, the surfaces of which carry C4-alkyl chains. The
separation of EPO from the proteinaceous impurities is based on
differences in the strength of hydrophobic interactions. Elution is
performed with an acetonitrile gradient in diluted trifluoroacetic
acid.
[0082] Preparative HPLC is performed using a stainless steel column
(filled with 2.8 to 3.2 liter of Vydac C4 silicagel). The
Hydroxyapatite Ultrogel eluate is acidified by adding
trifluoro-acetic acid and loaded onto the Vydac C4 column. For
washing and elution an acetonitrile gradient in diluted
trifluoroacetic acid is used. Fractions are collected and
immediately neutralized with phosphate buffer. The EPO fractions
which are within the IPC limits are pooled.
[0083] e) DEAE Sepharose Chromatography
[0084] The DEAE Sepharose (Pharmacia) material consists of
diethylaminoethyl (DEAE)--groups which are covalently bound to the
surface of Sepharose beads. The binding of EPO to the DEAE groups
is mediated by ionic interactions. Acetonitrile and trifluoroacetic
acid pass through the column without being retained. After these
substances have been washed off, trace impurities are removed by
washing the column with acetate buffer at a low pH. Then the column
is washed with neutral phosphate buffer and EPO is eluted with a
buffer with increased ionic strength.
[0085] The column is packed with DEAE Sepharose fast flow. The
column volume is adjusted to assure an EPO load in the range of
3-10 mg EPO/ml gel. The column is washed with water and
equilibration buffer (sodium/potassium phosphate). The pooled
fractions of the HPLC eluate are loaded and the column is washed
with equilibration buffer. Then the column is washed with washing
buffer (sodium acetate buffer) followed by washing with
equilibration buffer. Subsequently, EPO is eluted from the column
with elution buffer (sodium chloride, sodium/potassium phosphate)
and collected in a single fraction in accordance with the master
elution profile.
[0086] The eluate of the DEAE Sepharose column is adjusted to the
specified conductivity. The resulting drug substance is sterile
filtered into Teflon bottles and stored at -70.degree. C.
EXAMPLE 2
[0087] Pegylation of EPO with mPEG-SBA
[0088] EPO purified in accordance with the serum free procedure of
Example 1 (EPOsf) was homogeneous as determined by analytical
methods and showed the typical isoform pattern consisting of 8
isoforms. It had a specific biological activity of 190,000 IU/mg as
determined by the normocythaemic mouse assay. The pegylation
reagent used was a methoxy-PEG-SBA, which is a compound of Formula
II in which R is methyl; x is 3; and m is from 650 to 750 (avg.
about 680, corresponding to an average molecular weight of about 30
kDa).
[0089] Pegylation Reaction
[0090] To one hundred milligrams of EPOsf (9.71 ml of a 10.3 mg/ml
EPOsf stock, 5.48 .mu.mol) 10 ml of 0.1 M potassium phosphate
buffer, pH, 7.5 containing 506 mg of 30 kDa methoxy-PEG-SBA (16.5
.mu.mol) (obtained from Shearwater Polymers, Inc., Huntsville,
Ala.) was added and mixed for 2 h at room temperature
(20-23.degree. C.). The final protein concentration was 5 mg/ml and
the protein:PEG reagent ratio was 1:3. After two hours, the
reaction was stopped by adjusting the pH to 4.5 with glacial acetic
acid and stored at -20.degree. C., until ready for
purification.
[0091] Purification
[0092] 1. Conjugate Mixture: Approximately 28 ml of SP-SEPHAROSE FF
(sulfo-propyl cation exchange resin) was packed into an AMICON
glass column (2.2.times.7.5 cm) and equilibrated with 20 mM acetate
buffer pH, 4.5 at a flowrate of 150 ml/h. Six milliliters of the
reaction mixture containing 30 mg protein was diluted 5-fold with
the equilibration buffer and applied onto the column. Unadsorbed
materials were washed away with the buffer and the adsorbed PEG
conjugate mixture was eluted from the column with 0.175 M NaCl in
the equilibration buffer. Unmodified EPOsf still remaining on the
column was eluted with 750 mM NaCl. Column was reequilibrated in
the starting buffer. Samples were analyzed by SDS-PAGE and their
degree of pegylation were determined. It was found that the 0.175M
NaCl eluate contained, mono- as well as di- and trace amounts of
the tri-pegylated species, whereas the 750 mM NaCl eluate contained
unmodified EPOsf.
[0093] 2. Di-PEG and Mono-PEG-EPOsf: The purified conjugate mixture
eluted from the column in the previous step was diluted 4-fold with
the buffer and reapplied onto the column and washed as described.
Di-PEG-EPOsf and mono-PEG-EPOsf were separately eluted from the
column with 0.1M NaCl and 0.175 M NaCl, respectively. Elution was
also performed with 750 mM NaCl to elute any remaining unmodified
EPOsf.
[0094] Alternatively, the reaction mixture was diluted 5-fold with
the acetate buffer and applied onto the SP-Sepharose column
(.about.0.5 mg protein/ml gel). Column was washed and adsorbed
mono-PEG-EPOsf,di-PEG-EPO- sf and unmodified EPOsf were eluted as
described in the previous section.
[0095] Results
[0096] PEG-EPOsf was synthesized by chemically conjugating a linear
PEG molecule with a number average molecular weight of 30 kDa.
PEG-EPOsf was derived from the reaction between the primary amino
groups of EPOsf and the succinimidyl ester derivative of a 30 kDa
PEG-butyric acid, resulting in an amide bond.
[0097] Results are summarized in Table1. Purified conjugate mixture
comprised of mono- and di-PEG-EPOsf and was free of unmodified
EPOsf as determined by SDS-PAGE analysis. Conjugate mixture
accounted for 23.4 mg or 78% of the starting material. Cation
exchange chromatographic separation of mono- and di-PEG-EPOsf
indicated that mono- to di-PEG ratio in the conjugate mixture was
almost 1:1. After completion of the reaction, ratio of the
individual components of Mono:Di:Unmodified were 40:38:20 (%).
Overall yield was almost quantitative.
1TABLE 1 Summary of results of EPOsf pegylation Sample Protein (mg)
Yield (%) Rxn. Mix 30 100 Mono- 12.0 40 Di- 11.4 38 Unmod. 6.0 20
Conju. Mix. 23.4 78
EXAMPLE 3
[0098] Pegylation of EPO with mPEG-SPA
[0099] A different aliquot of the EPOsf used in Example 2 was
reacted with 30 kDa methoxy-PEG-SPA (Shearwater Polymers, Inc.,
Huntsville, Ala.). Reaction was performed at a protein:reagent
ratio of 1:2 and purification techniques were in accordance with
Example 2. Primarily the mono-pegylated species was produced.
EXAMPLE 4
[0100] In-vivo Activity of Pegylated EPO Determined by the
Normocythaemic Mouse Assay
[0101] The normocythaemic mouse bioassay is known in the art
(Pharm. Europa Spec. Issue Erythropoietin BRP Bio 1997(2)) and a
method in the monography of erythropoietin of Ph. Eur. BRP. The
samples were diluted with BSA-PBS. Normal healthy mice, 7-15 weeks
old, were administered s.c. 0.2 ml of the EPO-fraction containing
un-pegylated EPO or tri-, di- or mono-pegylated EPO from Example 2
or 3. Over a period of 6 days, blood was drawn by puncture of the
tail vein and diluted such that 1 .mu.l of blood was present in 1
ml of an 0.15 .mu.mol acridine orange staining solution. The
staining time was 3 to 10 minutes. The reticulocyte counts were
carried out microfluorometrically in a flow cytometer by analysis
of the red fluorescence histogram. The reticulocyte counts were
given in terms of absolute figures (per 30,000 blood cells
analyzed). For the data presented, each group consisted of 5 mice
per day, and the mice were bled only once.
[0102] In separate experiments, a single dose of unmodified EPO (25
ng of EPO), the PEG(SBA)-EPO mixture from Example 2 (10 ng of
conjugate), mono- and di-pegylated EPOs from Example 2 (10 ng of
conjugate), the PEG(SPA)-EPO from Example 3 (10 ng of conjugate),
and buffer solution were administered to mice. The results are
shown in Table 2. The results show the superior activity and the
prolonged half life of the pegylated EPO species indicated by the
significantly increased amounts of reticulocytes and the shift of
the reticulocytes count maximum using the same dose per mouse (10
ng), compared to a dose of 25 ng for unmodified EPO.
2 TABLE 2 PEG-EPO EPO 30 kDa SPA Mono 30K Di 30K SBA Conjugate
Control (Unmodified) PEG SBA SBA Mixture Buffer 72 h 1000 1393 1411
994 1328 857 96 h 500 1406 1501 926 1338 697 120 h .about.200 1100
1182 791 944 701 144 h .about.0 535 607 665 660 708
EXAMPLE 5
[0103] Preparation of Predominantly Mono-PEG-EPO
[0104] Pegylation Reaction
[0105] Starting with 100 mg (5.48 .mu.mol) of EPOsf in 100 mM
potassium phosphate buffer pH 7.5 prepared in accordance with
Example 1, there was added 329 mg (10.96 .mu.mol) of 30 kDa PEG-SBA
reagent dissolved in 3 ml 1 mM HCL. Enough 100 mM potassium
phosphate buffer pH 7.5 was added to make the reaction mixture
volume to 20 ml. The final protein concentration was 5 mg/ml and
the protein:PEG reagent ratio was 1:2. The reaction mixture was
mixed for 2 h at ambient temperature (20-22.degree. C.). After 2 h,
the reaction was stopped by adjusting the pH to 4.5 with glacial
acetic acid and stored frozen at -20.degree. C. until ready for
purification.
[0106] Purification
[0107] The reaction mixture from the previous step was diluted 1:5
with 10 mM sodium acetate, pH 4.5 and applied to 300 ml
SP-Sepharose FF (sulfopropyl cation exchange resin) packed into a
4.2.times.19 cm column. The column was previously equilibrated with
the same buffer. Column effluents were monitored at 280 nm with a
Gilson UV monitor and recorded with a Kipp and Zonen recorder. The
column was washed with 300 ml or 1 bed volume of equilibration
buffer to remove excess reagents, reaction byproducts and
oligomeric PEG-EPO. It was followed by washing with 2 bed volumes
of 100 mM NaCl to remove di-PEG-EPO. Mono-PEG-EPO was then eluted
with 200 mM NaCl. During elution of the mono-PEG-EPO, the first 50
ml of the protein peak was discarded and the mono-PEG-EPO was
collected as a 150 ml fraction. Unmodified EPOsf remaining on the
column was eluted with 750 mM NaCl. All elution buffers were made
in the equilibration buffer. All eluted samples were analyzed by
SDS-PAGE and by high performance Size Exclusion Chromatography
(SEC). The mono-PEG-EPO pool obtained from the 150 ml fraction,
which had no detectable unmodified EPOsf, was then concentrated to
.about.4.5-7.5 mg/ml and diafiltered into the storage buffer, 10 mM
potassium phosphate, 100 mM NaCl, pH 7.5.
Concentration/Diafiltration was performed with Millipore
Labscale.TM. TFF System fitted with 50 kDa cut off Millipore
Pellicon XL Biomax 50 membrane at ambient temperature. Concentrated
mono-PEG-EPO was sterile filtered and stored frozen at -20.degree.
C.
[0108] Approximately 75% of EPOsf was pegylated. After
purification, total yield was .about.30% mono-PEG-EPO with no
detectable unmodified EPOsf and around 25% di-PEG-EPO. Oligomers,
and unpegylated EPOsf accounted for the remaining protein. The
mono-PEG-EPO pool obtained from the 150 ml fraction contained
approximately 90% mono-PEG-EPO and approximately 10%
di-PEG-EPO.
EXAMPLE 6
[0109] Thermostability of EPO and Pegylated EPO in Various
Formulations: Analysis by DSC (Differential Scanning
Calorimetry)
[0110] It is generally accepted that the transition temperature of
thermal denaturation measured by differential scanning calorimetry
is a valid indicator for the thermostability of proteins.
Erythropoietin or pegylated erythropoietin (prepared according to
Example 3) solutions with concentrations between 0.6 and 1.2 mg/ml
were analyzed in various buffers with or without stabilizers by
means of a Nano-DSC (Calorimetric Sciences Corporation, Utah, USA)
at a heating rate of 2 K/min. An increase in transition temperature
indicates an increase in thermal stability of the protein. The
measured temperature values should not be understood as absolute
values but rather represent differences in the stability of the
individual formulations relative to one another.
[0111] In order to define the optimal pH of the formulation, the
pH-dependence of the thermal denaturation of pegylated
erythropoietin in the range between 4 and 9 was studied. The
protein samples were analyzed in 30 mM Na.sub.2HPO.sub.4, 30 mM
sodium citrate, 30 mM borate. FIG. 1 shows a plateau of maximal
transition temperature between about pH 6 to about pH 9 and a sharp
decrease below pH 5.5. This indicates that the optimal pH for
maximal thermal stability lies above pH 5.5. (FIG. 1).
[0112] In order to investigate the effect of ionic strength, the
phosphate concentration dependence of thermal denaturation was
determined. FIG. 2 shows that the thermal stability increases with
an increase in ionic strength of the formulation.
[0113] The influence of the buffer substance was also investigated
by DSC. From FIG. 3 one can see that the most suitable buffers or
additives for a high thermal stability are sulfate, citrate or
phosphate. Glycine, which is used as a buffer in currently
available formulations (see above) is not very suitable.
[0114] FIG. 4 shows that sulfate is also a suitable buffer/additive
at low pH (e.g. pH 6.2), whereas phosphate is less suitable at pH
6.2 compared to pH 7.5. This shows that sulfate keeps the thermal
stability high, even at low pH. This finding allows a formulation
at a pH between 6.0 and 6.5, without severe losses in thermal
stability of erythropoietin.
EXAMPLE 7
[0115] Aggregation of EPO and Peg-EPO Under Thermal Stress:
Analysis by SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel
Electrophoresis)
[0116] In order to investigate the effect of heat stress on the
erythropoietin protein, samples in different formulations were
exposed to heat stress (20 min 80.degree. C.) and analyzed by
sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) under reducing (with DTT in sample buffer) and
non-reducing (w/o DTT in sample buffer) conditions. This method
allows the detection of covalent aggregate formation. As outlined
above, aggregate formation is one of the major degradation pathways
of proteins and therefore should be prevented in pharmaceutical
formulations of proteins. Aggregates that are detectable in the
absence of reducing agent (e.g. DTT) and not detectable in the
presence of reducing agent are highly likely to be formed by
incorrect disulfide bridging, an oxidation reaction, under heat
stress. FIG. 5 shows the pH dependency of aggregation under heat
stress. This experiment clearly shows that the formation of
aggregates is suppressed at a pH below 6.5. The higher the pH, the
higher the amount of aggregation. Most of the aggregates that are
formed can be reduced by treatment of the samples with a reducing
agent during SDS-PAGE, suggesting that a great portion of the
aggregates that are formed under heat stress are disulfide-bridged
dimers, oligomers and higher order aggregates. Taken together, his
indicates that the formation of aggregates can be prevented to a
great extent by keeping the pH of the formulation at or below pH
6.5.
[0117] FIG. 5: Dependency of peg-EPO aggregation on pH. Peg-EPO
samples prepared accord to Example 3 were subjected to heat stress
(as described above) and then analyzed by SDS-PAGE. Proteins were
stained with silver. Lane 1: molecular weight standard. Lane 2: pH
5. Lane 3: pH 5, reduced. Lane 4: pH 6. Lane 5: pH 6, reduced. Lane
6: pH 6.5. Lane 7: pH 6.5, reduced. Lane 8: pH 7. Lane 9: pH 7,
reduced. Lane 10: peg-EPO, unstressed.
[0118] The formation of aggregates can also be prevented by the use
of antioxidants. FIG. 6 shows that the use of 1 mg/ml
acetylcysteine as an antioxidant prevents the formation of
aggregates under heat stress. Therefore, it is useful to use an
antioxidant, like e.g. acetylcysteine at a low pH, e.g. pH 6.2, to
prevent aggregate formation under heat stress.
[0119] FIG. 6: Peg-EPO aggregation can be prevented by pH 6.2
and/or acetylcysteine. Peg-EPO samples prepared according to
Example 3 were subjected to heat stress (as described above) and
then analyzed by SDS-PAGE. Proteins were stained with silver. Lane
1: peg-EPO, unstressed. Lane 2: pH 7.5, stressed. Lane 3: pH 6.2,
stressed. Lane 4: pH 6.2, stressed, reduced. Lane 5: pH 7.5, 1
mg/ml acetylcysteine, stressed. Lane 6: pH 7.5, 1 mg/ml
acetylcysteine, stressed, reduced.
Example 8
[0120] Stability of Peg-EPO in Various Formulations at 4, 25, 30
and 40.degree. C.
[0121] Pegylated EPO prepared according to Example 3 in various
formulations is incubated at several temperatures. At indicated
time points, samples are taken and the stability is assessed by
reversed phase high performance chromatography (rpHPLC), high
performance size exclusion chromatography (SEC) and sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Table 3
compares the stability of peg-EPO in various formulations at
several temperatures. These data clearly show the superiority of
the herein enclosed formulations regarding protein recovery and
aggregation.
3TABLE 3 Stability of peg-EPO in various formulations at several
temperatures: Aggregation at % recovery after 40.degree. C. Formu-
PegEPO one month at detectable lation* (.mu.g/ml) 4.degree. C.
25.degree. C. 30.degree. C. 40.degree. C. (+/-) A 10 95 92 n.d. 66
- B 10 93 90 n.d. 64 - C 10 115 115 111 105 - D 10 100 99 102 93 -
E 50 n.d. 106 99 84 + F 50 98 100 98 89 - G 50 101 101 101 100 - H
50 105 103 101 102 - I 50 103 101 104 104 - A 100 100 99 n.d. 79 +
B 100 103 100 n.d. 77 + C 100 103 102 103 88 - D 100 105 106 106 98
- E 400 98 96 89 88 + F 400 99 97 96 93 - G 400 98 96 100 106 - H
400 107 108 102 97 - I 400 104 105 98 103 - *the formulations are:
formulation A: 10 mM sodium phosphate, 100 mM sodium chloride, pH
7.5. formulation B: 200 mM glycine, pH 7.1. formulation C: 10 mM
sodium phosphate, 140 mM sodium sulfate, pH 6.2. formulation D: 10
mM sodium phosphate, 40 mM sodium sulfate, 4% (w/v) mannitol, pH
6.2. formulation E: 10 mM sodium phosphate, 100 mM NaCl, pH 7.0.
formulation F: 10 mM sodium phosphate, 120 mM sodium sulfate, pH
6.2 formulation G: 10 mM sodium phosphate, 40 mM sodium sulfate, 3%
(w/v) mannitol, pH 6.2. formulation H: 10 mM sodium phosphate, 40
mM sodium sulfate, 3% (w/v) mannitol, 7.5 .mu.M CaCl.sub.2, pH 6.2.
formulation I: 50 mM arginine, 100 mM sodium sulfate, 1 mM
CaCl.sub.2, pH 6.2.
[0122]
Sequence CWU 1
1
3 1 165 PRT Homo sapiens 1 Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg
Val Leu Glu Arg Tyr Leu 1 5 10 15 Leu Glu Ala Lys Glu Ala Glu Asn
Ile Thr Thr Gly Cys Ala Glu His 20 25 30 Cys Ser Leu Asn Glu Asn
Ile Thr Val Pro Asp Thr Lys Val Asn Phe 35 40 45 Tyr Ala Trp Lys
Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp 50 55 60 Gln Gly
Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu 65 70 75 80
Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp 85
90 95 Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala
Leu 100 105 110 Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala
Ser Ala Ala 115 120 125 Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg
Lys Leu Phe Arg Val 130 135 140 Tyr Ser Asn Phe Leu Arg Gly Lys Leu
Lys Leu Tyr Thr Gly Glu Ala 145 150 155 160 Cys Arg Thr Gly Asp 165
2 166 PRT Homo sapiens 2 Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg
Val Leu Glu Arg Tyr Leu 1 5 10 15 Leu Glu Ala Lys Glu Ala Glu Asn
Ile Thr Thr Gly Cys Ala Glu His 20 25 30 Cys Ser Leu Asn Glu Asn
Ile Thr Val Pro Asp Thr Lys Val Asn Phe 35 40 45 Tyr Ala Trp Lys
Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp 50 55 60 Gln Gly
Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu 65 70 75 80
Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp 85
90 95 Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala
Leu 100 105 110 Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala
Ser Ala Ala 115 120 125 Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg
Lys Leu Phe Arg Val 130 135 140 Tyr Ser Asn Phe Leu Arg Gly Lys Leu
Lys Leu Tyr Thr Gly Glu Ala 145 150 155 160 Cys Arg Thr Gly Asp Arg
165 3 28 PRT Homo sapiens 3 Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser
Leu Pro Ser Pro Ser Arg 1 5 10 15 Leu Pro Gly Pro Ser Asp Thr Pro
Ile Leu Pro Gln 20 25
* * * * *